Alpha 2.0
Login Register
» Authors » Lucas De Mendonca

Lucas De Mendonca

Explore the profile of Lucas De Mendonca including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 38
Followers 0
Related Specialties
Public Health
General Medicine
Top 10 Co-Authors
Jo-Anne Manski-Nankervis
Barbara Hunter
Patricia R M Rocco
Cynthia Dos Santos Samary
Brian Nicholson
George Fishman
Pedro L Silva
Benny Wang
Jon Emery
Pedro Leme Silva
Published In
Stem Cell Res Ther
BJGP Open
Br J Pharmacol
BMJ Open
Aust J Gen Pract
Affiliations
Soon will be listed here.
Recent Articles
1.
Have interventions aimed at assisting general practitioners in facilitating earlier diagnosis of type 1 diabetes in children been successful in preventing acute complications? A systematic review
Beccia C, McMorrow R, Donald A, De Mendonca L, White M, Hunter B, et al.
BMJ Open . 2024 Oct; 14(10):e085635. PMID: 39353690
Background: Diabetic ketoacidosis (DKA) is a life-threatening emergency that can result from delayed diagnosis of type 1 diabetes mellitus (T1DM). Three-quarters of Australian children with a new diagnosis of T1DM...
2.
A scoping review of unexpected weight loss and cancer: risk, guidelines, and recommendations for follow-up in primary care
Martinez-Gutierrez J, De Mendonca L, Ly P, Lee A, Hunter B, Manski-Nankervis J, et al.
BJGP Open . 2024 Jul; 8(4). PMID: 39054298
Background: Cancer diagnoses often begin with consultations with GPs, but the non-specific nature of symptoms can lead to delayed diagnosis. Unexpected weight loss (UWL) is a common non-specific symptom linked...
3.
Using primary care data for research: What are the issues and potential solutions?
Cheah R, Canaway R, Hallinan C, De Mendonca L, Manski-Nankervis J
Aust J Gen Pract . 2024 Jun; 53(6):408-411. PMID: 38840382
Background: Interest in using primary care data for research is growing with increasing recognition of its potential for improving healthcare. Many issues exist, some inherent in the data and others...
4.
Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension
Felix N, De Mendonca L, Braga C, Silva J, Samary C, Vieira J, et al.
Br J Pharmacol . 2019 Jul; 176(23):4462-4473. PMID: 31351013
Background And Purpose: Pulmonary arterial hypertension (PAH) is a progressive disease associated with high morbidity and mortality, despite advances in medical therapy. We compared the effects of infigratinib (NVP-BGJ398), a...
5.
Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension
De Mendonca L, Felix N, Blanco N, da Silva J, Ferreira T, Abreu S, et al.
Stem Cell Res Ther . 2017 Oct; 8(1):220. PMID: 28974252
Background: Experimental research has reported beneficial effects of mesenchymal stromal cell (MSC) therapy in pulmonary arterial hypertension (PAH). However, these studies either were based on prophylactic protocols or assessed basic...